Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain & Program in Solid Tumors, Center for Applied Medical Research (CIMA), Madrid, 31008, Spain.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Future Oncol. 2022 Jul;18(23):2505-2536. doi: 10.2217/fon-2022-0206. Epub 2022 Jul 6.
We reviewed clinical data for niraparib monotherapy in -mutated (m) epithelial ovarian cancer (OC), contextualizing results with data from other poly(ADP-ribose) polymerase inhibitors (PARPis). Niraparib reduced the likelihood of progression or death by 60% as first-line maintenance therapy and by 73-78% in recurrent disease. In heavily pretreated OC, efficacy was greater in the m versus non-m cohort. Quality-of-life (QoL) was maintained throughout treatment. Adverse events were consistent with the known niraparib safety profile. Cumulative efficacy, safety and QoL evidence demonstrate niraparib maintenance monotherapy has a positive benefit:risk ratio in m OC. Niraparib significantly improved progression-free survival as first-line maintenance therapy in all patients with OC (i.e., of any biomarker status).
我们回顾了尼拉帕利单药治疗 - 突变（m）上皮性卵巢癌（OC）的临床数据，将结果与其他聚（ADP-核糖）聚合酶抑制剂（PARPis）的数据进行了对比。尼拉帕利作为一线维持治疗，使疾病进展或死亡的可能性降低了 60%，在复发性疾病中降低了 73-78%。在大量预处理的 OC 中，m 组比非 m 组的疗效更好。整个治疗过程中，生活质量（QoL）得到了维持。不良反应与已知的尼拉帕利安全性特征一致。累积疗效、安全性和 QoL 证据表明，尼拉帕利维持单药治疗在 m OC 中具有正的获益：风险比。尼拉帕利显著改善了所有 OC 患者（即任何生物标志物状态）的无进展生存期作为一线维持治疗。
